BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20502722)

  • 21. [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases].
    Janszky J
    Ideggyogy Sz; 2009 Nov; 62(11-12):383-9. PubMed ID: 20025128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zonisamide.
    Leppik IE
    Epilepsia; 1999; 40 Suppl 5():S23-9. PubMed ID: 10530691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of endoplasmic reticulum stress in Parkinson's disease.
    Tsujii S; Ishisaka M; Hara H
    Eur J Pharmacol; 2015 Oct; 765():154-6. PubMed ID: 26297973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical pharmacology and therapeutic drug monitoring of zonisamide.
    Mimaki T
    Ther Drug Monit; 1998 Dec; 20(6):593-7. PubMed ID: 9853971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of zonisamide on resting tremor resistant to antiparkinsonian medication].
    Nakanishi I; Kohmoto J; Miwa H; Kondo T
    No To Shinkei; 2003 Aug; 55(8):685-9. PubMed ID: 13677302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug Insight: new drugs in development for Parkinson's disease.
    Colosimo C; Fabbrini G; Berardelli A
    Nat Clin Pract Neurol; 2006 Nov; 2(11):600-10. PubMed ID: 17057747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of zonisamide in a case of Parkinson's disease with intractable resting and re-emergent tremor.
    Iijima M; Osawa M; Kobayashi M; Uchiyama S
    Eur J Neurol; 2011 Apr; 18(4):e43-4. PubMed ID: 21159065
    [No Abstract]   [Full Text] [Related]  

  • 29. Recent advances in Parkinson's disease.
    Vécsei L
    Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract]   [Full Text] [Related]  

  • 30. Zonisamide: its pharmacology, efficacy and safety in clinical trials.
    Brodie MJ; Ben-Menachem E; Chouette I; Giorgi L
    Acta Neurol Scand Suppl; 2012; (194):19-28. PubMed ID: 23106522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New small molecules for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1077-86. PubMed ID: 20645881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures.
    Baulac M; Leppik IE
    Epilepsy Res; 2007 Jul; 75(2-3):75-83. PubMed ID: 17553670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson's disease.
    Ueda Y; Tokashiki S; Kanemaru A; Kojima T
    Biochem Biophys Res Commun; 2012 Nov; 428(3):401-4. PubMed ID: 23103374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Parkinson's Disease: amantadine, zonisamide, dabrafenib].
    Okamoto T
    Brain Nerve; 2019 Sep; 71(9):953-959. PubMed ID: 31506397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zonisamide: a new antiepileptic drug.
    Sobieszek G; Borowicz KK; Kimber-Trojnar Z; Małek R; Piskorska B; Czuczwar SJ
    Pol J Pharmacol; 2003; 55(5):683-9. PubMed ID: 14704463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selegiline's neuroprotective capacity revisited.
    Riederer P; Lachenmayer L
    J Neural Transm (Vienna); 2003 Nov; 110(11):1273-8. PubMed ID: 14628191
    [No Abstract]   [Full Text] [Related]  

  • 37. Zonisamide: new drug. No advantage in refractory partial epilepsy.
    Prescrire Int; 2007 Jun; 16(89):95-7. PubMed ID: 17582922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genome-wide association study identifies zonisamide responsive gene in Parkinson's disease patients.
    Cha PC; Satake W; Ando-Kanagawa Y; Yamamoto K; Murata M; Toda T
    J Hum Genet; 2020 Aug; 65(8):693-704. PubMed ID: 32355309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation.
    Asanuma M; Miyazaki I; Diaz-Corrales FJ; Miyoshi K; Ogawa N; Murata M
    Neurosci Res; 2008 Jan; 60(1):106-13. PubMed ID: 18022268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zonisamide in patients with essential tremor and Parkinson's disease.
    Bermejo PE
    Mov Disord; 2007 Oct; 22(14):2137-8. PubMed ID: 17853481
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.